Cost-effectiveness of triplet therapies in metastatic hormone-sensitive prostate cancer used in PEACE-1 and ARASENS

被引：0
|
作者：
Lester-Coll, Nataniel Hernan
Benjamin, David Joseph
Ribault, Helene
Foulon, Stephanie
Fizazi, Karim
Rezazadeh, Arash
机构：
[1] Univ Vermont, Larner Coll Med, Burlington, VT USA
[2] Hoag Family Canc Inst, Newport Beach, CA USA
[3] Unicancer, Paris, France
[4] Gustave Roussy Inst, Villejuif, France
[5] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[6] Univ Calif Irvine, Div Hematol Oncol, Orange, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.222
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
222
引用
收藏
页码：222 / 222
页数：1
相关论文
共 50 条
  • [1] A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
    Sung, W. W.
    Choi, H. C.
    Luk, P. H.
    So, T. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1326 - S1326
  • [2] A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer
    Sung, Winnie W. Y.
    Choi, Horace C. W.
    Luk, Peter H. Y.
    So, Tsz Him
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer
    Sathianathen, Niranjan J.
    Alarid-Escudero, Fernando
    Kuntz, Karen M.
    Lawrentschuk, Nathan
    Bolton, Damien M.
    Murphy, Declan G.
    Kim, Simon P.
    Konety, Badrinath R.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 649 - 655
  • [4] Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer
    Beca, Jaclyn
    Majeed, Habeeb
    Chan, Kelvin K. W.
    Hotte, Sebastian J.
    Loblaw, Andrew
    Hoch, Jeffrey S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (12): : 396 - 403
  • [5] COST-EFFECTIVENESS OF SYSTEMIC TREATMENT INTENSIFICATION IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Sathianathen, Niranjan
    Lawrentschuk, Nathan
    Azad, Arun
    Konety, Badrinath
    Murphy, Declan
    JOURNAL OF UROLOGY, 2023, 209 : E492 - E492
  • [6] Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?
    Sathianathen, Niranjan J.
    Lawrentschuk, Nathan
    Konety, Badrinath
    Azad, Arun A.
    Corcoran, Niall M.
    Bolton, Damien M.
    Murphy, Declan G.
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (04): : 870 - 876
  • [7] Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer
    Ding, Haiying
    Li, Shujing
    Xu, Xinglu
    Xu, Weiben
    He, Chaoneng
    Xin, Wenxiu
    Zhan, ZhaJun
    Fang, Luo
    BMJ OPEN, 2024, 14 (07): : 1 - 6
  • [8] Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
    Hindie, Elif
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3873 - 3875
  • [9] Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer
    Barbier, Michaela C.
    Tomonaga, Yuki
    Menges, Dominik
    Yebyo, Henock G.
    Haile, Sarah R.
    Puhan, Milo A.
    Schwenkglenks, Matthias
    PLOS ONE, 2022, 17 (11):
  • [10] Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India
    Gupta, Nidhi
    Gupta, Dharna
    Vaska, Kiran Gopal
    Prinja, Shankar
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2024, 22 (03) : 415 - 426
12345